Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
KYNB
$5.49
+3.98%
KYNB
· Kyntra Bio, Inc.
Market Cap
$21.38M
Shares
4.05M
Volume · Oct 20
13.55K
Avg daily vol (3M)
19.56K
All webcasts
Earnings call · FY2023 Q4
Kyntra Bio, Inc. (KYNB) Q4 2023 Earnings Call
Revenue · derived Q4
-$73.81M
-314.8% YoY
Net income · derived Q4
-$56.23M
Forward guidance
2 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Feb 26, 2024.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
FibroGen's full year net product revenue under U.S. GAAP
2024
|
$120M – $135M | GAAP | |
|
Full year roxadustat net sales in China by FibroGen and the JDE
2024
|
$300M – $340M | — |
SEC filing · Item 2.02
8-K earnings release
Filed Feb 26, 2024 · complete as-filed document
SEC periodic report
10-K report
Filed Feb 26, 2024 · complete as-filed document